GW&K Investment Management LLC boosted its position in Dova Pharmaceuticals Inc (NASDAQ:DOVA) by 39.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 201,625 shares of the company’s stock after purchasing an additional 56,926 shares during the period. GW&K Investment Management LLC’s holdings in Dova Pharmaceuticals were worth $4,228,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DOVA. BlackRock Inc. increased its stake in Dova Pharmaceuticals by 76.5% in the 2nd quarter. BlackRock Inc. now owns 1,144,920 shares of the company’s stock valued at $34,257,000 after purchasing an additional 496,306 shares in the last quarter. Nexthera Capital LP increased its stake in Dova Pharmaceuticals by 44.4% in the 2nd quarter. Nexthera Capital LP now owns 820,348 shares of the company’s stock valued at $24,545,000 after purchasing an additional 252,105 shares in the last quarter. Northern Trust Corp grew its holdings in Dova Pharmaceuticals by 154.2% during the 2nd quarter. Northern Trust Corp now owns 163,116 shares of the company’s stock valued at $4,881,000 after buying an additional 98,955 shares during the last quarter. Raymond James & Associates acquired a new stake in Dova Pharmaceuticals during the 2nd quarter valued at $1,465,000. Finally, Wells Fargo & Company MN grew its holdings in Dova Pharmaceuticals by 12.7% during the 2nd quarter. Wells Fargo & Company MN now owns 380,455 shares of the company’s stock valued at $11,383,000 after buying an additional 42,819 shares during the last quarter. 36.53% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts have commented on the company. Zacks Investment Research cut Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 30th. BidaskClub cut Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 2nd. Raymond James assumed coverage on Dova Pharmaceuticals in a report on Wednesday, August 29th. They set an “outperform” rating and a $44.00 target price on the stock. Finally, Leerink Swann lowered their target price on Dova Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating on the stock in a report on Tuesday, September 4th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. Dova Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $33.20.

Shares of NASDAQ:DOVA opened at $15.39 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 7.50 and a quick ratio of 7.40. Dova Pharmaceuticals Inc has a one year low of $14.09 and a one year high of $37.00.

Dova Pharmaceuticals (NASDAQ:DOVA) last announced its earnings results on Thursday, November 8th. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.12. The company had revenue of $2.93 million for the quarter, compared to analyst estimates of $2.66 million. Sell-side analysts expect that Dova Pharmaceuticals Inc will post -2.63 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Dova Pharmaceuticals Inc (DOVA) Shares Bought by GW&K Investment Management LLC” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2018/11/16/dova-pharmaceuticals-inc-dova-shares-bought-by-gwk-investment-management-llc.html.

Dova Pharmaceuticals Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.

See Also: Short Selling Stocks and Day Traders

Want to see what other hedge funds are holding DOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dova Pharmaceuticals Inc (NASDAQ:DOVA).

Institutional Ownership by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.